Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer

First Head-to-Head Randomized Control Study (RCT) Reinforces Early Patient Experience Benefits and 12-month Durability of the UroLift™ System versus Rezūm™¹
Three-Year Data Demonstrate Sustained Reduction in Gastrointestinal Toxicity with Barrigel™ Rectal Spacer²

Las Vegas, Nevada (UroToday.com) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, announced the Interventional Urology Business Unit has released new clinical data across two major urological congresses, reinforcing the value of the UroLift™ System and Barrigel™ rectal spacer in improving patient-centered outcomes across benign prostatic hyperplasia (BPH) and prostate cancer care. Teleflex Interventional Urology innovations help urologists treat medical needs while ensuring patients can recover and maintain their quality of life long after treatment.

In parallel with Teleflex’s long-term strategy to significantly streamline the Teleflex business and narrow focus to the critical care and high-acuity hospital end-markets, the company’s Interventional Urology business unit continues to drive clinical value as it prepares for its divestiture in the second half of 2026.

Data presented at the 2026 American Urological Association (AUA) Annual Meeting in Washington, DC. May 15 – 18 and the European Society for Radiotherapy & Oncology (ESTRO) Congress held in Stockholm May 15 – 19 highlight early patient experience following BPH treatment1 with the UroLift™ System and sustained reductions in radiation-associated toxicity for prostate cancer patients who received Barrigel™ rectal spacer.²

CLEAR RCT: First Head-to-Head Comparison of Minimally Invasive Surgical Therapies (MISTs) Demonstrates Favorable Early Patient Experience with the UroLift™ System*

At AUA 2026, Dr. Bilal Chughtai**, a urologist with Northwell Health, Garden City, N.Y., presented 12-month findings from the CLEAR (Comparing UroLift™ Experience Against Rezūm™) randomized controlled trial, the first prospective, multicenter, head-to-head RCT comparing MISTs for BPH.¹

The study evaluated key endpoints including catheter independence, symptom improvement, patient experience, and sexual function.¹

Key study endpoints of the study:

Catheter independence from day three through day seven was significantly better among UroLift™ System patients compared to Rezūm™ patients, with 3 percent requiring catheter versus 20 percent (p=.02) respectively¹
Early patient experience was better for the UroLift™ System patients compared to Rezūm™ patients¹
UroLift™ System and Rezūm™ subjects had similar durability through 12 months¹
Patients’ sexual function† was preserved through 12 months with the UroLift™ System¹

“What stands out in our CLEAR RCT study is the consistency of the early patient experience advantages with the UroLift™ System, particularly catheter independence, rapid recovery, and preservation of sexual function, which are critical factors for both patients and physicians when selecting a treatment approach,” said Dr. Bilal Chughtai**, a urologist practicing in Syosset, N.Y.

Barrigel™ Rectal Spacer Three-Year Data Demonstrate Sustained Reduction in Radiation-Associated Toxicity*

At ESTRO 2026, new three-year outcomes presented by Dr. Martin King** highlighted the long-term safety and effectiveness of Barrigel™ rectal spacer.²

Key endpoints of the study:

Patients in the Barrigel™ rectal spacer arm of the study experienced a continued Grade 2+ toxicity benefit sustained through three years. Zero percent of the Barrigel™ rectal spacer patients experienced Grade 2+ toxicity versus 10 percent in the control arm²
Fewer patients with greater than one centimeter of apical spacing had a decline in bowel quality of life at 36 months versus control²

These results demonstrate a durable benefit for the Barrigel™ rectal spacer subjects sustained through three years, reinforcing the role of rectal spacing in protecting bowel function during and after radiation therapy.²

“The three-year data further validate the clinical value of Barrigel™ rectal spacer, demonstrating sustained and clinically meaningful reductions in gastrointestinal toxicity,” said Martin King**, MD, PhD, presenter and radiation oncologist with the Dana-Farber Brigham Cancer Center, Harvard Medical School Associate Professor of Radiation Oncology. “Reducing radiation treatment-related toxicity is essential for prostate cancer patients, and these findings support the continued adoption of rectal spacing as a standard component of care.”²

“These data reflect our prostate health leadership and ongoing commitment to advancing evidence-based, patient-centered solutions across the urology care continuum,” said Travis Gay, President and General Manager, Interventional Urology, Teleflex. “From improving early recovery and preserving sexual function in BPH patients with the UroLift™ System to delivering durable protection against radiation-related rectal toxicity with Barrigel™ spacer, we are focused on technologies that meaningfully improve patients’ lives.”

Source: Teleflex Incorporated. (2026. Teleflex Showcases New Clinical Data at Leading Urological Congresses Highlighting Patient Experience Advantages of the UroLift™ System and Long-Term Toxicity Reduction with Barrigel™ Rectal Spacer [Press release]. https://www.urolift.com/patients/about-us/press-releases/teleflex-showcases-new-clinical-data-at-leading-urological-congresses.

Login